Maryland, USA-based Emergent BioSolutions says that preliminary results from a recently-completed, randomized, placebo-controlled Phase II clinical study demonstrated that its single-dose, drinkable typhoid vaccine candidate achieved key endpoints for safety and immunogenicity. This recruited children between five and 14 years of age, a total of 101 of whom received the vaccine candidate and 50 were given placebo. The vaccine candidate and placebo were allocated in a blinded manner. This study, which was conducted in Vietnam, is the first of this product in a pediatric population in a region where typhoid is endemic and was performed in collaboration with Oxford University of the UK and the Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, and financially supported by the Wellcome Trust.
The data from this Phase II clinical study, which is still being analyzed, support the following key findings:
- the vaccine was immunogenic and met the pre-defined criterion of an overall immune response rate of greater than 50%, with 95% confidence;
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze